Full Press Release Details
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers.
IDYA
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Key Takeaway: IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers